Skip to content

Released Nov 12, 2024, after the close

10-Q filed Nov 12, 2024, 43 days after period end · 0001628280-24-047284

Q3 2024 · 10-Q
Revenue$89.05M+60.6% vs Q3 2023+58.4% vs Q2 2024
Net Income-$56.40MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$1.08N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$55,204,000N/M
Operating Cash Flowderived-$103,501,000N/M
Free Cash Flowderived-$118,590,000N/M
Margins · derived
Operating margin-62.0%+454.7 pt vs Q3 2023
Net margin-63.3%+483.1 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$89.05M$55.43M$66.40M$77.61M
Net Income-$56.40M-$302.89M-$670.13M-$101.88M
EPS Diluted-$1.08-$6.21-$0.41-$0.08

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR